Product
Burosumab
Aliases
Crysvita®, KRN23, UX023
6 clinical trials
6 indications
Indication
X-linked hypophosphatemiaIndication
Tumor-Induced OsteomalaciaIndication
X-linked HypophosphatemiaIndication
Tumor-Induced Osteomalacia (TIO)Indication
Epidermal Nevus SyndromeIndication
X-Linked HypophosphatemiaClinical trial
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2023-10-04
Clinical trial
A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated OsteomalaciaStatus: Completed, Estimated PCD: 2017-07-27
Clinical trial
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2017-04-20
Clinical trial
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGERStatus: Completed, Estimated PCD: 2023-03-17
Clinical trial
An Observational, Prospective, European, Multicentre, Mixed Methods Study to Describe the Lived Experience of X-Linked Hypophosphatemia (XLH) for Adolescents at End of Skeletal GrowthStatus: Completed, Estimated PCD: 2024-05-22